Stephane Debeugny
Overview
Explore the profile of Stephane Debeugny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liegey J, Cremer A, Lucas L, Gosse P, Debeugny S, Rubin S, et al.
J Hum Hypertens
. 2024 Nov;
39(1):38-45.
PMID: 39487319
Malignant hypertension (MHT) crisis triggers widespread microvascular damage, particularly in the brain. Despite recent MRI evidence highlighting acute cerebral injuries during MHT crises, follow-up data remain scarce. This study seeks...
2.
Boulestreau R, Lorthioir A, Dreau H, Persu A, Cremer A, Tharaux P, et al.
J Hypertens
. 2024 Oct;
42(12):2131-2138.
PMID: 39351849
Background: Malignant hypertension has not disappeared and remains the most severe form of hypertension. More than 100 years after its description, many points remain unanswered. Mechanisms, definitions, and optimal treatment...
3.
de Guillebon M, Garcia R, Debeugny S, Bader H, Probst V, Bidegain N, et al.
Heart Rhythm
. 2024 May;
21(12):2530-2535.
PMID: 38810921
Background: Electrocardiographic screening before subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation is unsuccessful in around 10% of cases. A personalized screening method, by slightly moving the electrodes, to obtain a better R/T...
4.
Bonnan M, Debeugny S
Front Neurol
. 2023 Dec;
14:1305093.
PMID: 38130834
Stroke is a rare and severe complication of giant cell arteritis (GCA). Although early diagnosis and treatment initiation are essential, the mechanism of stroke is often related to vasculitis complicated...
5.
Bonnan M, Courtade H, Debeugny S
Mult Scler Relat Disord
. 2023 Oct;
79:105050.
PMID: 37806232
Background: Changes in immunoglobulin (Ig) levels may occur in association with various drugs targeting immunity, including disease-modifying drugs (DMD) and corticosteroids (CS) used to treat multiple sclerosis (MS). However, kinetics...
6.
Bonnan M, Courtade H, Debeugny S
Mult Scler Relat Disord
. 2023 Sep;
79:105039.
PMID: 37774601
Background: Changes in immunoglobulin (Ig) levels may occur in association with various drugs targeting immunity, including those used to treat multiple sclerosis (MS). However, influence of high-dose corticosteroids (CS) is...
7.
Boulestreau R, Lorthioir A, Persu A, Sarafidis P, Cremer A, Tharaux P, et al.
J Hypertens
. 2023 Jan;
41(3):453-458.
PMID: 36719959
Background: Malignant hypertension has not disappeared and is associated with a poor prognosis. Yet, so far, it has received limited attention from the medical community. Guidelines are mainly based on...
8.
de Guillebon M, Tixier R, Debeugny S, Bader H, Delarche N
J Interv Card Electrophysiol
. 2022 Nov;
66(3):521-524.
PMID: 36441427
No abstract available.
9.
Boulestreau R, Lucas L, Cremer A, Debeugny S, Rubin S, Gaudissard J, et al.
J Hypertens
. 2021 Aug;
39(12):2463-2469.
PMID: 34343146
Background: Acute and diffuse microvascular damage characterizes malignant hypertension (MHT), the deadliest form of hypertension (HTN). Although its ophthalmological, renal and cardiological repercussions are well known, brain involvement is considered...
10.
Bonnan M, Ferrari S, Courtade H, Money P, Desblache P, Barroso B, et al.
Mult Scler Int
. 2021 Mar;
2021:8813498.
PMID: 33763241
Background: The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A...